[Treatment of borderline personality disorder with atypical antipsychotic drugs].
Pharmacotherapy of Borderline personality disorder with atypical antipsychotics has recently been the subject of several mostly small studies and case reports. In contrast to the frequent clinical use of this substance class in borderline patients the amount of data on that subject is still sparse. The clinical data gathered thus far suggest a potential use of atypical antipsychotics in the areas of psychotic symptoms, impulsivity and possibly affective symptoms. The drugs were sufficiently well tolerated; however, the observation period in most studies was short and the dosage low. The current set of clinical data does not support the frequently applied polypharmacy. However, recent data suggest that a therapeutic approach combining atypical antipsychotics and psychotherapy may reveal synergistic effects. Future trials should study larger sample sizes over a longer period of time. Open questions are the required dose and the optimal treatment duration.
Mobascher
A
A
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Heinrich-Heine-Universität , Bergische Landstrasse 2, 40629 , Düsseldorf. arian.mobascher@lvr.de
Mobascher
J
J
Schmahl
C
C
Malevani
J
J
D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage* / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001883:Borderline Personality Disorder / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000639:trends*; D006801:Humans; D010818:Practice Patterns, Physicians' / Q000639:trends
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents